{"id":"W2081649373","doi":"10.1007/s10637-005-5860-y","title":"A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Cancer; Medicine; Investigational Drugs; Drug; Cancer drugs; Family medicine; Gerontology; Internal medicine; Clinical trial; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003024252,0.0002771067,0.001072753,0.0002270653,0.00008844762,0.00001377334,0.000660679,0.00009034017,0.00009407355],"category_scores_gemma":[0.003762177,0.0001754364,0.0001438303,0.001418557,0.000923373,0.0002301941,0.0002114604,0.0006048689,6.402267e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000524621,"about_ca_system_score_gemma":0.02490734,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.2103229,"about_ca_topic_score_gemma":0.3048217,"domain_scores_codex":[0.9914793,0.001045,0.002572709,0.0004592684,0.004133163,0.0003105111],"domain_scores_gemma":[0.9956384,0.0006858687,0.00159283,0.0004584101,0.001241681,0.0003828263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001273283,0.01691784,0.947262,0.0001357455,0.0005404166,0.00000200083,0.007089611,0.003322297,0.0001217685,0.0003112383,0.01689153,0.006132259],"study_design_scores_gemma":[0.04801336,0.002802613,0.9426417,0.0009089281,0.0001960143,0.000001744044,0.001168288,0.0006381269,0.001038063,0.0008663049,0.001525231,0.0001996695],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893396,0.00004411583,0.000001650054,0.004982414,0.0002327543,0.005060238,0.0002031437,0.00000991382,0.0001261104],"genre_scores_gemma":[0.9973891,0.000001920867,0.001137484,0.0005896441,0.0003268343,0.0002017729,0.00005339641,0.00002932783,0.0002705449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0944988,"threshold_uncertainty_score":0.9806206,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1409265698095374,"score_gpt":0.4577079910447914,"score_spread":0.3167814212352541,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}